“Unfortunately, the mutations we identified in this subtype of form cancer are very similar to the mutations that are found in many other forms of cancer.
The research was conducted by engineers from Northwestern and Miraca Therapeutics, a neuro-oncology company based in San Diego, California.
Moriah Spence, the study senior author and an associate professor of dermatology at Feinberg, said the drugs have the potential to dramatically improve survival rates for patients who are diagnosed with ER+ breast cancer.
yearly, according to the American Cancer Society.